Jay Shree Mathivanan, Victor Violet Dhayabaran, Mary Rajathei David, Muthugobal Bagayalakshmi Karuna Nidhi, Karuppasamy Muthuvel Prasath, Suvaiyarasan Suvaithenamudhan
{"title":"Application of Deep Learning Neural Networks in Computer-aided Drug Discovery: A Review","authors":"Jay Shree Mathivanan, Victor Violet Dhayabaran, Mary Rajathei David, Muthugobal Bagayalakshmi Karuna Nidhi, Karuppasamy Muthuvel Prasath, Suvaiyarasan Suvaithenamudhan","doi":"10.2174/0115748936276510231123121404","DOIUrl":null,"url":null,"abstract":": Computer-aided drug design has an important role in drug development and design. It has become a thriving area of research in the pharmaceutical industry to accelerate the drug discovery process. Deep learning, a subdivision of artificial intelligence, is widely applied to advance new drug development and design opportunities. This article reviews the recent technology that uses deep learning techniques to ameliorate the understanding of drug-target interactions in computer-aided drug discovery based on the prior knowledge acquired from various literature. In general, deep learning models can be trained to predict the binding affinity between the protein-ligand complexes and protein structures or generate protein-ligand complexes in structure-based drug discovery. In other words, artificial neural networks and deep learning algorithms, especially graph convolutional neural networks and generative adversarial networks, can be applied to drug discovery. Graph convolutional neural network effectively captures the interactions and structural information between atoms and molecules, which can be enforced to predict the binding affinity between protein and ligand. Also, the ligand molecules with the desired properties can be generated using generative adversarial networks.","PeriodicalId":10801,"journal":{"name":"Current Bioinformatics","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Bioinformatics","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.2174/0115748936276510231123121404","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
: Computer-aided drug design has an important role in drug development and design. It has become a thriving area of research in the pharmaceutical industry to accelerate the drug discovery process. Deep learning, a subdivision of artificial intelligence, is widely applied to advance new drug development and design opportunities. This article reviews the recent technology that uses deep learning techniques to ameliorate the understanding of drug-target interactions in computer-aided drug discovery based on the prior knowledge acquired from various literature. In general, deep learning models can be trained to predict the binding affinity between the protein-ligand complexes and protein structures or generate protein-ligand complexes in structure-based drug discovery. In other words, artificial neural networks and deep learning algorithms, especially graph convolutional neural networks and generative adversarial networks, can be applied to drug discovery. Graph convolutional neural network effectively captures the interactions and structural information between atoms and molecules, which can be enforced to predict the binding affinity between protein and ligand. Also, the ligand molecules with the desired properties can be generated using generative adversarial networks.
期刊介绍:
Current Bioinformatics aims to publish all the latest and outstanding developments in bioinformatics. Each issue contains a series of timely, in-depth/mini-reviews, research papers and guest edited thematic issues written by leaders in the field, covering a wide range of the integration of biology with computer and information science.
The journal focuses on advances in computational molecular/structural biology, encompassing areas such as computing in biomedicine and genomics, computational proteomics and systems biology, and metabolic pathway engineering. Developments in these fields have direct implications on key issues related to health care, medicine, genetic disorders, development of agricultural products, renewable energy, environmental protection, etc.